NDAORALCAPSULE, EXTENDED RELEASE
Lifecycle
Pre-Launch
Data completeness
2/8 — Basic
ISORDIL (isosorbide dinitrate) by Thayer Medical is clinical pharmacology the principal pharmacological action of isosorbide dinitrate is relaxation of vascular smooth muscle and consequent dilatation of peripheral arteries and veins, especially the latter.
Drug data last refreshed 4h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ISORDIL (isosorbide dinitrate) is an organic nitrate vasodilator indicated for angina pectoris that works by relaxing vascular smooth muscle, promoting peripheral blood pooling and reducing cardiac preload and afterload. The drug dilates both peripheral and coronary arteries and veins, with the relative contribution of these mechanisms to efficacy remaining undefined. It is administered orally as an extended-release capsule.
$0.068MPart D
Pre-LaunchEarly-stage product with minimal current claims volume signals opportunity to build launch infrastructure and establish market presence in the crowded nitrate category.
Mechanism of Action
CLINICAL PHARMACOLOGY The principal pharmacological action of isosorbide dinitrate is relaxation of vascular smooth muscle and consequent dilatation of peripheral arteries and veins, especially the latter. Dilatation of the veins promotes peripheral pooling of blood and decreases venous return to…
Worked on ISORDIL at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.